2.92
0.14 (5.04%)
| Previous Close | 2.78 |
| Open | 2.78 |
| Volume | 1,643,383 |
| Avg. Volume (3M) | 1,621,092 |
| Market Cap | 828,438,528 |
| Price / Book | 2.69 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Diluted EPS (TTM) | -0.570 |
| Total Debt/Equity (MRQ) | 12.72% |
| Current Ratio (MRQ) | 12.35 |
| Operating Cash Flow (TTM) | -107.72 M |
| Levered Free Cash Flow (TTM) | -91.89 M |
| Return on Assets (TTM) | -22.16% |
| Return on Equity (TTM) | -45.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Erasca, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | 0.25 |
|
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 11.69% |
| % Held by Institutions | 84.38% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 5.00 (Guggenheim, 71.23%) | Buy |
| Median | 4.50 (54.11%) | |
| Low | 4.00 (Stifel, 36.99%) | Buy |
| Average | 4.50 (54.11%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 2.56 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 14 Nov 2025 | 5.00 (71.23%) | Buy | 2.58 |
| Stifel | 16 Oct 2025 | 4.00 (36.99%) | Buy | 2.53 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 25 Nov 2025 | Announcement | Erasca to Present at the 8th Annual Evercore Healthcare Conference |
| 12 Nov 2025 | Announcement | Erasca Reports Third Quarter 2025 Business Updates and Financial Results |
| 06 Nov 2025 | Announcement | Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015 |
| 04 Nov 2025 | Announcement | Erasca to Present at Upcoming Conferences in November |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |